Community prevalence of SARS-CoV-2 in England: Results from the ONS Coronavirus Infection Survey Pilot

Objective: To estimate the percentage of individuals infected with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) over time in the community in England and to quantify risk factors. Design: Repeated cross-sectional surveys of population-representative households with longitudinal follow-up if consent given. Setting: England. Participants: 34,992 Individuals aged 2 years and over from 16,722 private residential households. Data were collected in a pilot phase of the survey between 26 April and 28 June 2020. Main outcome measures: Percentage of individuals in the community testing positive for SARS-CoV-2 RNA using throat and nose swabs. Individuals were asked about any symptoms and potential risk factors. Results: The percentage of people in private-residential households testing positive for SARS-CoV-2 reduced from 0.32% (95% credible interval (CrI) 0.19% to 0.52%) on 26 April to 0.08% (95% CrI 0.05% to 0.12%) on 28 June, although the prevalence stabilised near the end of the pilot. Factors associated with an increased risk of testing positive included having a job with direct patient contact (relative exposure (RE) 4.06, 95% CrI 2.42 to 6.77)), working outside the home (RE 2.49, 95% CrI 1.39 to 4.45), and having had contact with a hospital (RE 2.20, 95% CrI 1.09 to 4.16 for having been to a hospital individually and RE 1.95, 95% CrI 0.81 to 4.09 for a household member having been to a hospital). In 133 visits where individuals tested positive, 82 (61%, 95% CrI 53% to 69%) reported no symptoms, stably over time. Conclusion: The percentage of SARS-CoV-2 positive individuals declined between 26 April and 28 June 2020. Positive tests commonly occurred without symptoms being reported. Working outside your home was an important risk factor, indicating that continued monitoring for SARS-CoV-2 in the community will be essential for early detection of increases in infections following return to work and other relaxations of control measures.

[1]  J. Lessler,et al.  Estimating the burden of SARS-CoV-2 in France , 2020, Science.

[2]  P. McCullagh Regression Models for Ordinal Data , 1980 .

[3]  Kari Stefansson,et al.  Spread of SARS-CoV-2 in the Icelandic Population , 2020, The New England journal of medicine.

[4]  Quentin J. Leclerc,et al.  Quantifying the impact of physical distance measures on the transmission of COVID-19 in the UK , 2020, BMC Medicine.

[5]  J. Carlin,et al.  Multilevel regression and poststratification as a modeling approach for estimating population quantities in large population health studies: A simulation study , 2019, Biometrical journal. Biometrische Zeitschrift.

[6]  Paul-Christian Bürkner,et al.  brms: An R Package for Bayesian Multilevel Models Using Stan , 2017 .

[7]  T. Rea,et al.  Epidemiology of Covid-19 in a Long-Term Care Facility in King County, Washington , 2020, The New England journal of medicine.

[8]  P. Glasziou,et al.  Estimating the extent of true asymptomatic COVID-19 and its potential for community transmission: systematic review and meta-analysis , 2020, medRxiv.

[9]  J. Gabry,et al.  Bayesian Applied Regression Modeling via Stan , 2016 .

[10]  N. P. H. Lan,et al.  The Natural History and Transmission Potential of Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infection , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  Peng Gong,et al.  Global supply-chain effects of COVID-19 control measures , 2020, Nature Human Behaviour.

[12]  R. Geskus,et al.  The natural history and transmission potential of asymptomatic SARS-CoV-2 infection , 2020, medRxiv.

[13]  S. Wood Thin plate regression splines , 2003 .

[14]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[15]  J. Klausner,et al.  Self-Collected Oral Fluid and Nasal Swabs Demonstrate Comparable Sensitivity to Clinician Collected Nasopharyngeal Swabs for Covid-19 Detection , 2020, medRxiv.

[16]  Marta Betoldi In Labour , 2003 .

[17]  F. Lewis,et al.  A tutorial in estimating the prevalence of disease in humans and animals in the absence of a gold standard diagnostic , 2012, Emerging Themes in Epidemiology.

[18]  P. Glasziou,et al.  Estimating the extent of asymptomatic COVID-19 and its potential for community transmission: Systematic review and meta-analysis. , 2020, Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada.

[19]  S. Merler,et al.  Probability of symptoms and critical disease after SARS-CoV-2 infection , 2020, 2006.08471.

[20]  N. G. Davies,et al.  Effects of non-pharmaceutical interventions on COVID-19 cases, deaths, and demand for hospital services in the UK: a modelling study , 2020, The Lancet Public Health.

[21]  E. Lavezzo,et al.  Suppression of COVID-19 outbreak in the municipality of Vo, Italy , 2020, medRxiv.